Core Viewpoint - The company, Shandong Kaisheng New Materials Co., Ltd., has announced its profit distribution plan for the first three quarters of 2025, which includes a cash dividend of 0.50 RMB per 10 shares and no stock bonus, based on a total share capital of 420,647,429 shares as of September 30, 2025 [1][3][17]. Profit Distribution Plan - The profit distribution plan was approved by the company's board on October 22, 2025, and will distribute a total cash dividend of 21,032,371.45 RMB [1][3]. - The cash dividend will be distributed to all shareholders registered by the close of trading on November 17, 2025, with the ex-dividend date set for November 18, 2025 [3][4]. Share Capital Changes - As of the announcement date, the company's total share capital has increased from 420,647,429 shares to 420,647,487 shares, with the profit distribution plan remaining unchanged [2]. Taxation Details - The cash dividend will be subject to different tax rates based on the type of shareholder, with specific provisions for Hong Kong investors and domestic investors holding different types of shares [3]. Convertible Bond Adjustment - Following the profit distribution, the conversion price of the company's convertible bonds (Kaisheng Convertible Bonds) will be adjusted from 20.01 RMB per share to 19.96 RMB per share, effective from November 18, 2025 [6][18].

Core Viewpoint - The equity change is primarily due to the exchange of bonds by the bondholders of Huabang Health, resulting in a decrease in the controlling shareholder's stake from 32.49% to 31.68%, which touches the 1% integer multiple threshold [1][5]. Group 1: Equity Change Details - Huabang Health issued non-public exchangeable bonds with a total scale of 600 million yuan, with an initial conversion price of 14.88 yuan per share, adjusted to 14.83 yuan per share after the 2024 annual equity distribution [1]. - The exchange period for the bonds began on October 23, 2025, and will last until April 21, 2028, allowing bondholders to convert their bonds into company shares [2]. - From October 23 to October 27, 2025, bondholders exchanged a total of 21,186,747 shares, reducing Huabang Health's stake from 39.75% to 34.72% [2]. - On October 28, 2025, an additional 4,369,515 shares were exchanged, further reducing Huabang Health's stake to 33.68% [3]. - Between October 29 and October 30, 2025, bondholders exchanged 4,973,021 shares, bringing Huabang Health's stake down to 32.49% [3]. - On November 3, 2025, the final exchange of 3,425,485 shares was reported, resulting in a decrease of Huabang Health's stake to 31.68% [3]. Group 2: Regulatory Compliance and Impact - The equity change does not trigger a mandatory tender offer and will not lead to changes in the controlling shareholder or actual controller, nor will it significantly impact the company's governance structure or ongoing operations [1][5]. - All shares involved in the equity change retain voting rights, and there are no restrictions on the transfer of these shares [5]. - The company will continue to monitor the exchange situation and fulfill its information disclosure obligations as required by relevant laws and regulations [5].